Viking Therapeutics, Inc.

Following GSK’s $1.2bn acquisition of privately held Boston Pharmaceuticals’ metabolic dysfunction-associated steatohepatitis (MASH) candidate efimosfermin on 14 May, the industry is wondering what re

There have been numerous deals centered on metabolic dysfunction-associated steatohepatitis (MASH) over roughly the past decade, but the 14 May deal in which GSK acquired Boston Pharmaceuticals’ Phase

Investor outlook for Pfizer’s oral GLP-1 agonist danuglipron was already dampened, but now the obesity drug has officially been discontinued, leaving the big pharma on the sidelines of the obesity dru

For big pharma companies who want a major stake in the ballooning obesity market, opportunities to license in a mid-stage asset are dwindling. Roche claimed one of the top unlicensed candidates on 12